NLRP3 and immune system disorder: Through its dual mechanisms of “direct NLRP3 inhibition” and “regulation of protein stability,” Tranilast provides multidimensional evidence supporting the repurposing of this drug for treating NLRP3-driven cardiovascular and immune disorders (175).